Seroprevalence of Human Leptospirosis in a Tertiary Care Hospital
DOI:
https://doi.org/10.51168/8zj4jf79Keywords:
Leptospirosis, seroprevalence, acute febrile illness, zoonosis, Andhra Pradesh, tertiary care, epidemiologyAbstract
Background: Leptospirosis is an important zoonotic cause of acute febrile illness in tropical regions, yet its local burden is frequently underestimated because clinical manifestations overlap with other infections and laboratory testing is not uniformly applied.
Objectives: To estimate Leptospira seroprevalence among tested patients at Government Medical College, Ongole, and describe its distribution by age, sex, patient category, residence, and month of sample collection.
Methods: A prospective, hospital-based cross-sectional study was conducted at Government Medical College, Ongole, a tertiary-care teaching institution located in Prakasam district, Andhra Pradesh, India, from 1 May 2025 to 30 April 2026. The institution serves patients from Ongole and the surrounding urban, peri-urban, and rural communities, including referrals from neighbouring districts. A total of 110 eligible patients undergoing Leptospira testing were consecutively included. Seroprevalence was calculated with an exact 95% confidence interval, and categorical associations were assessed using two-sided Fisher's exact tests.
Results: Among 110 individuals tested, 30 were seropositive, yielding a seroprevalence of 27.3% (95% CI: 19.2%-36.6%). The mean age was 10.9 ± 12.7 years, and 98 participants (89.1%) were younger than 16 years. Seropositivity was significantly higher among females than males (39.1% vs 18.8%; p=0.029). All seropositive cases were inpatients and residents of Prakasam district; positivity was 30.6% in Prakasam district versus 0% in other districts (p=0.034). Month-wise positivity varied from 0% to 50.0%, with the highest proportions observed in January and July.
Conclusion: Human leptospirosis represented a substantial proportion of tested patients in this tertiary-care setting. The one-year findings support continued diagnostic suspicion, timely laboratory evaluation of compatible febrile illness, and strengthened surveillance across the hospital catchment area.
Recommendations: Strengthened laboratory surveillance, complete recording of clinical and exposure variables, and year-round testing of clinically suspected cases are recommended. Larger multicentre prospective studies should characterize risk factors, diagnostic performance, disease severity, and outcomes.
References
1. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-71. . PMID: 14652202. https://doi.org/10.1016/S1473-3099(03)00830-2
2. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326. PMID: 11292640. https://doi.org/10.1128/CMR.14.2.296-326.2001
3. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898. PMID: 26379143. https://doi.org/10.1371/journal.pntd.0003898
4. Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. PLoS Negl Trop Dis. 2015;9(10):e0004122. PMID: 26431366. https://doi.org/10.1371/journal.pntd.0004122
5. Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97. doi:10.1007/978-3-662-45059-8_5. PMID: 25388133.
https://doi.org/10.1007/978-3-662-45059-8_5
6. Velineni S, Asuthkar S, Umabala P, Lakshmi V, Sritharan M. Serological evaluation of leptospirosis in Hyderabad Andhra Pradesh: a retrospective hospital-based study. Indian J Med Microbiol. 2007;25(1):24-7. PMID: 17377348. https://doi.org/10.4103/0255-0857.31057
7. Sohan L, Shyamal B, Kumar TS, Malini M, Ravi K, Venkatesh V, et al. Studies on leptospirosis outbreaks in Peddamandem Mandal of Chittoor district, Andhra Pradesh. J Commun Dis. 2008;40(2):127-32. PMID: 19301697.
8. Chaudhry R, Das A, Premlatha MM, Choudhary A, Chourasia BK, Chandel DS, et al. Serological & molecular approaches for diagnosis of leptospirosis in a tertiary care hospital in north India: a 10-year study. Indian J Med Res. 2013;137(4):785-90. PMID: 23703348.
9. Sethi S, Sharma N, Kakkar N, Taneja J, Chatterjee SS, Banga SS, et al. Increasing trends of leptospirosis in northern India: a clinico-epidemiological study. PLoS Negl Trop Dis. 2010;4(1):e579. PMID: 20084097. https://doi.org/10.1371/journal.pntd.0000579
10. Bhatia M, Umapathy BL, Navaneeth BV. An evaluation of dark field microscopy, culture and commercial serological kits in the diagnosis of leptospirosis. Indian J Med Microbiol. 2015;33(3):416-21. PMID: 26068347. https://doi.org/10.4103/0255-0857.158570
11. M�rch K, Manoharan A, Chandy S, Chacko N, Alvarez-Uria G, Patil S, et al. Acute undifferentiated fever in India: a multicentre study of aetiology and diagnostic accuracy. BMC Infect Dis. 2017;17(1):665. PMID: 28978319. https://doi.org/10.1186/s12879-017-2764-3
12. Jacob SM, Geethalakshmi S, Karthikeyan S, Durairaj A, Gopal P, Ramamoorthy V, et al. A 3-year retrospective analysis on the prevalence of antileptospiral antibodies among children in Chennai City, India. J Med Microbiol. 2018;67(12):1706-10. PMID: 30372412.
https://doi.org/10.1099/jmm.0.000825
13. Dhanashree B, Shenoy S. Seropositivity for dengue and Leptospira IgM among patients with acute febrile illness: an indicator of co-infection? Germs. 2021;11(2):155-62. PMID: 34422688. https://doi.org/10.18683/germs.2021.1253
14. Shukla S, Mittal V, Karoli R, Singh P, Singh A. Leptospirosis in central & eastern Uttar Pradesh, an underreported disease: a prospective cross-sectional study. Indian J Med Res. 2022;155(1):66-72. PMID: 35859430. https://doi.org/10.4103/ijmr.IJMR_1811_19
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr. Sulakshana Sony Cheemala, Dr. Vijaya Swetha. Vuppalapati, Dr. N. Padma Priya

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.














